GUANGSHEN RAIL (00525) released its interim results, with a net profit attributable to shareholders of 1.19 billion yuan, an increase of 7.32% year-on-year.
Guangshen Railway Company Limited (00525) announced its interim performance for the six months ended June 30, 2026. The group achieved operating revenue of 14.789 billion yuan, an increase of 5.87% year-on-year; the net profit attributable to shareholders of the listed company was 1.19 billion yuan, an increase of 7.32% year-on-year; basic earnings per share were 0.168 yuan.
GUANGSHEN RAIL (00525) released its interim results for the six months ending June 30, 2026, reporting operating revenue of 14.789 billion yuan, an increase of 5.87% year-on-year; net profit attributable to shareholders of the listed company was 1.19 billion yuan, up 7.32% year-on-year; basic earnings per share were 0.168 yuan.
During the reporting period, the company, as a railway transport enterprise, primarily operated railroad passenger and freight transport services, and cooperated with Hong Kong Railway Company to operate cross-border passenger train services. Additionally, it was entrusted to provide railway transport services for other railway companies, including the Wuhan-Guangzhou Passenger Dedicated Line, Guangzhou-Zhuhai Intercity, Guangzhou-Shenzhen-Hong Kong Passenger Dedicated Line, Guangzhou-Zhuhai Railway, Xiamen-Shenzhen Railway, Guangdong Railway, Nanguang Railway, Guizhou-Guangxi Railway, Maozhan Railway, Shenmao Railway, Meishan Passenger Dedicated Line, Northeast Railway, Ganzhou-Shenzhen Railway, Nansha Port Railway, Bohe Port Railway, Guangshan Railway, Meilong Railway, and Guangzhanz Railway.
Related Articles

YAN PALACE (01497) repurchased 70,000 shares at a cost of HKD 424,800 on August 25.

CHINA CHENGTONG (00217) announced a positive profit forecast, expecting a shareholder's profit of approximately HKD 43.8 million for the first half of the year, a significant increase of about 343% year-on-year.

INNOVENT BIO (01801) announced its interim results, with a profit of 1.253 billion yuan during the period, representing a year-on-year growth of 50.2%.
YAN PALACE (01497) repurchased 70,000 shares at a cost of HKD 424,800 on August 25.

CHINA CHENGTONG (00217) announced a positive profit forecast, expecting a shareholder's profit of approximately HKD 43.8 million for the first half of the year, a significant increase of about 343% year-on-year.

INNOVENT BIO (01801) announced its interim results, with a profit of 1.253 billion yuan during the period, representing a year-on-year growth of 50.2%.

RECOMMEND





